Across both cohorts, the CA125 measurements achieved an AUC of 0.70 (0.56—0.85), 0.93 (0.87–0.98) and 0.87 (0.80—0.94) in separating benign from early stage (I and II), late stage (III and IV) and any stage (I-IV) tumours, respectively. The gene discussed is MUC16; the disease is neoplasm.